Product Description
BAY3375968 is an antibody that binds to a protein called CCR8 which is located on the surface of regulatory T cells. This leads to a reduction in regulatory T cells and further inhibits their immune suppressive activity, so that the immune response against cancer can be strengthened as observed in animal models. Animal studies also showed that BAY3375968 may add more anti-cancer effect to immunotherapy with PD-1/PD-L1 inhibitors when used in combination. All of these previous observations need to be confirmed in humans. (Sourced from: https://clinicaltrials.bayer.com/study/21820/)
Mechanisms of Action: CCR8 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bayer
Company Location: LEVERKUSEN 2M D-51368
Company CEO: Werner Baumann
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Canada, China, France, Singapore, Spain, United Kingdom, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Breast Cancer|Head and Neck Cancer|Melanoma|Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05537740 |
NCT05537740 | P1 |
Active, not recruiting |
Melanoma|Squamous Cell Carcinoma|Head and Neck Cancer|Breast Cancer|Non-Small-Cell Lung Cancer |
2026-07-07 |
50% |
2025-10-24 |
Primary Completion Date|Primary Endpoints|Treatments |
CTR20242872 |
CTR20242872 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
None |
2025-07-15 |
Patient Enrollment|Treatments |
Recent News Events
Date |
Type |
Title |
|---|